UFPT Quote, Financials, Valuation and Earnings

Insulet has a net margin of 11.37% compared to UFP Technologies's net margin of 16.85%. UFP Technologies's return on equity of 18.87% beat Insulet's return on equity of 43.11%.

UFP Technologies has a consensus price target of $381.00, signalling upside risk potential of 84.24%. On the other hand Insulet has an analysts' consensus of $312.27 which suggests that it could grow by 19.78%. Given that UFP Technologies has higher upside potential than Insulet, analysts believe UFP Technologies is more attractive than Insulet.

UFP Technologies has a beta of 1.079, which suggesting that the stock is 7.904% more volatile than S&P 500. In comparison Insulet has a beta of 1.300, suggesting its more volatile than the S&P 500 by 30.008%.

UFP Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UFP Technologies pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

UFP Technologies quarterly revenues are $144.1M, which are smaller than Insulet quarterly revenues of $597.5M. UFP Technologies's net income of $16.4M is lower than Insulet's net income of $100.7M. Notably, UFP Technologies's price-to-earnings ratio is 27.21x while Insulet's PE ratio is 45.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UFP Technologies is 3.19x versus 9.30x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Repligen has a net margin of 11.37% compared to UFP Technologies's net margin of -20.22%. UFP Technologies's return on equity of 18.87% beat Repligen's return on equity of -1.29%.

UFP Technologies has a consensus price target of $381.00, signalling upside risk potential of 84.24%. On the other hand Repligen has an analysts' consensus of $187.60 which suggests that it could grow by 29.6%. Given that UFP Technologies has higher upside potential than Repligen, analysts believe UFP Technologies is more attractive than Repligen.

UFP Technologies has a beta of 1.079, which suggesting that the stock is 7.904% more volatile than S&P 500. In comparison Repligen has a beta of 1.266, suggesting its more volatile than the S&P 500 by 26.606%.

UFP Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UFP Technologies pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

UFP Technologies quarterly revenues are $144.1M, which are smaller than Repligen quarterly revenues of $167.5M. UFP Technologies's net income of $16.4M is higher than Repligen's net income of -$33.9M. Notably, UFP Technologies's price-to-earnings ratio is 27.21x while Repligen's PE ratio is 633.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UFP Technologies is 3.19x versus 12.84x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex has a net margin of 11.37% compared to UFP Technologies's net margin of -17.18%. UFP Technologies's return on equity of 18.87% beat Teleflex's return on equity of 1.57%.

UFP Technologies has a consensus price target of $381.00, signalling upside risk potential of 84.24%. On the other hand Teleflex has an analysts' consensus of $161.82 which suggests that it could grow by 19.68%. Given that UFP Technologies has higher upside potential than Teleflex, analysts believe UFP Technologies is more attractive than Teleflex.

UFP Technologies has a beta of 1.079, which suggesting that the stock is 7.904% more volatile than S&P 500. In comparison Teleflex has a beta of 1.191, suggesting its more volatile than the S&P 500 by 19.095%.

UFP Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex offers a yield of 1.01% to investors and pays a quarterly dividend of $0.34 per share. UFP Technologies pays -- of its earnings as a dividend. Teleflex pays out 91.2% of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UFP Technologies quarterly revenues are $144.1M, which are smaller than Teleflex quarterly revenues of $795.4M. UFP Technologies's net income of $16.4M is higher than Teleflex's net income of -$136.7M. Notably, UFP Technologies's price-to-earnings ratio is 27.21x while Teleflex's PE ratio is 95.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UFP Technologies is 3.19x versus 2.09x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of 11.37% compared to UFP Technologies's net margin of 12.87%. UFP Technologies's return on equity of 18.87% beat West Pharmaceutical Services's return on equity of 17.47%.

UFP Technologies has a consensus price target of $381.00, signalling upside risk potential of 84.24%. On the other hand West Pharmaceutical Services has an analysts' consensus of $281.83 which suggests that it could grow by 31.36%. Given that UFP Technologies has higher upside potential than West Pharmaceutical Services, analysts believe UFP Technologies is more attractive than West Pharmaceutical Services.

UFP Technologies has a beta of 1.079, which suggesting that the stock is 7.904% more volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.221, suggesting its more volatile than the S&P 500 by 22.112%.

UFP Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services offers a yield of 0.38% to investors and pays a quarterly dividend of $0.21 per share. UFP Technologies pays -- of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UFP Technologies quarterly revenues are $144.1M, which are smaller than West Pharmaceutical Services quarterly revenues of $698M. UFP Technologies's net income of $16.4M is lower than West Pharmaceutical Services's net income of $89.8M. Notably, UFP Technologies's price-to-earnings ratio is 27.21x while West Pharmaceutical Services's PE ratio is 33.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UFP Technologies is 3.19x versus 5.44x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.